IVX Health raises $100M to accelerate expansion for infusion centers
WEBSeptember 21, 2021 By Sean Whooley. IVX Health announced today that it completed a $100 million Series F minority investment round from Great Hill Partners. Nashville, Tennessee-based IVX plans to utilize the funding to accelerate its entry into new markets in 2022 and beyond in its effort to make its outpatient infusion centers the country’s ...
Inovio to scale up production of smart delivery device for potential ...
WEBJul 24, 2020 · Inovio Pharmaceuticals (NSDQ:INO) announced that it received $71 million from the U.S. Defense Dept. to support its Cellectra 3PSP smart device.. Funding from the DoD is set to support large-scale manufacturing for the Cellectra 3PSP and the procurement of Cellectra 2000 devices, which are used to deliver Inovio’s INO-4800 COVID-19 vaccine candidate directly into the skin.
Smiths Medical recall affects nearly 86,000 syringe pumps
WEBMarch 7, 2024 By Sean Whooley. Smiths Medical issued a recall for its Medfusion Model 3500 syringe pump due to issues associated with earlier software versions. The ICU Medical unit issued the recall as a correction — not a product removal. It affects 85,961 pumps distributed between Aug. 9, 2022, and Aug. 15, 2023.
FDA clears Abbott’s next-gen FreeStyle Libre 3 14-day CGM
WEBMay 31, 2022 · The sensor for the next-generation FreeStyle Libre 3 CGM is the same size as two U.S. pennies stacked together. [Image courtesy of Abbott] Abbott (NYSE:ABT) announced today that it received FDA clearance for its next-generation FreeStyle Libre 3 continuous glucose monitor. FDA clearance for the latest iteration of the company’s FreeStyle Libre platform — designed as the smallest and ...
GlucoTrack provides positive update on next-gen glucose monitor
WEBJun 22, 2022 · GlucoTrack (Nasdaq:GCTK) announced today that its second-generation glucose monitor device has shown promising results in analyses.. Rutherford, New Jersey-based GlucoTrack — formerly known as Integrity Applications (Nasdaq:IGAP) — earlier this year completed lab testing of the non-invasive GlucoTrack 2.0 clinical prototype system and has observed better-than-expected accuracy and ...
Eli Lilly to build $1B manufacturing facility for injectable products ...
WEBJan 28, 2022 · Eli Lilly (NYSE:LLY) announced today that it plans to invest more than $1 billion to create a new manufacturing site in North Carolina.. Indianapolis-based Eli Lilly’s new facility, which it expects will create nearly 600 jobs in Concord, North Carolina, will manufacture parenteral (injectable) products and devices while increasing the company’s manufacturing capacity.
Diabeloop, SOOIL partner on automated insulin delivery technology
WEBJun 3, 2022 · Paris-based Diabeloop, which develops therapeutic artificial intelligence (AI) applied to insulin delivery, and SOOIL will pursue and expand upon technical integration between their platforms, building on cooperation that was initiated in February 2020. According to a news release, the companies in 2020 launched a large clinical study of 184 ...
BD’s Alaris pump hit with another serious recall
WEBApr 30, 2021 · The latest recall of Alaris Model 8100 covers 2,452 pumps distributed between July 10, 2020, and February 18, 2021. There have been 62 complaints reported about this device issue and one death may have been related to this recall, according to an FDA news release. No other injuries have been …
Manufacturing drug device products: challenges and best practices
WEBAug 14, 2017 · Companies use Resonetic’s laser micro-manufacturing capabilities to build a wide array of drug delivery devices, including implants and drug-eluting infusion devices. “There are multiple market drivers to use laser micro-manufacturing to fabricate drug delivery devices,” he said. “Novel pulmonary, ophthalmic and nebulizer delivery ...
BD completes spinoff of Embecta diabetes company
WEBApr 1, 2022 · BD (NYSE:BDX) announced today that the planned spinoff of its diabetes business — named Embecta (Nasdaq:EMBC)— has been made official.. Franklin Lakes, New Jersey-based BD announced its intention to spinoff the diabetes business in May 2021. Near the end of 2021, it unveiled the soon-to-be independent, publicly-traded company’s name as “Embecta,” with plans to complete the spinoff ...